© 2020 MJH Life Sciences™ and Drug Topics. All rights reserved.
Dermatology
Chronic Inflammatory Skin Diseases and Shingles Risk
September 03, 2020
Study suggests higher hospitalization rate for some skin diseases.
FDA Approves Dupilumab for Atopic Dermatitis in Children
May 26, 2020
Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.
Phase 3 Study: Apremilast Shows Efficacy in Mild-to-Moderate Plaque Psoriasis
May 08, 2020
Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.
FDA OKs Crisaborole for Use in Children as Young as 3 Months of Age
March 24, 2020
Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.
Abrocitinib Improves Moderate-to-Severe Atopic Dermatitis in Phase 3 Study
March 23, 2020
Phase 3 clinical data demonstrate abrocitinib’s efficacy and safety in treating moderate-to-severe atopic dermatitis in adults.
New Phase 3 Data on Baricitinib Efficacy in Atopic Dermatitis
February 04, 2020
Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.
FDA Grants Priority Review to Dupilumab for Children with Atopic Dermatitis
January 28, 2020
If approved, dupilumab (Dupixent, Regeneron and Sanofi) would be indicated for use as an add-on maintenance treatment for children ages 6 to 11 years with moderate-to-severe atopic dermatitis.
What Pharmacists Need to Know About Psoriasis Medications
January 17, 2020
Pharmacists can play an integral role in managing patients with psoriasis through medication therapies and lifestyle modifications.
Minocycline Topical Foam 4% Approved by FDA for Acne Vulgaris
October 21, 2019
Available for prescribing starting January 2020
Cetirizine IV Approved for Pediatric Acute Urticaria
October 18, 2019
Originally approved in 1995 for use in adults only.
FDA Approves Trifarotene Cream for Acne Treatment
October 08, 2019
First new treatment of its kind in over 20 years.
FDA Approves Hadlima (Adalimumab-bwwd) Biosimilar
July 23, 2019
TNF blocker biosimilar to Humira (adalimumab, Abbvie).
FDA Approves Sorilux (Calcipotriene) for Adolescent Plaque Psoriasis
May 23, 2019
Vitamin D analog foam indicated for topical treatment of plaque psoriasis in teens.
Duobrii (halobetasol propionate and tazarotene) Moisturizing Lotion for Plaque Psoriasis
April 25, 2019
New lotion from Ortho Dermatologics expected June 2019.
AbbVie’s Risankizumab-rzaa Granted Regulatory Approval
April 24, 2019
Indicated for adults with moderate to severe plaque psoriasis.
Fentanyl Patches Recalled for Mislabeling
April 23, 2019
Alvogen, Inc., has issued a recall of two lots of Fentanyl Transdermal System 12 mcg/h transdermal patches to the consumer level.
Understanding and Treating Postherpetic Itch
April 11, 2019
An itchy post-shingles complication can be challenging to control.
What Do Pharmacists Have to Do with Dermatology?
June 12, 2018
Skin problems often require complex (and expensive) drugs, so how can you help?
FDA approves OTC antifungal Tolnaftate-D
August 19, 2011
Apricus Biosciences and its wholly owned subsidiary, NexMed USA, have received FDA approval for over-the-counter sales of antifungal drug Tolnaftate-D, containing the company's NexACT technology, which transiently loosens the tight junction between the cells of the sealed skin to allow more permeation.